Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

IMAGING

The role of multiparametric MRI in biopsy-naive prostate cancer

Results of recent trials have shown the superiority of mpMRI to TRUS-guided systematic biopsy for detecting clinically significant prostate cancer. However, only performing an mpMRI risks missing MRI-invisible lesions and, therefore, there might be added value in performing both targeted and systematic biopsies in biopsy-naive patients.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Siddiqui, M. M. et al. Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. JAMA 313, 390–397 (2015).

    Article  CAS  Google Scholar 

  2. Kasivisvanathan, V. et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis. N. Engl. J. Med. 378, 1767–1777 (2018).

    Article  Google Scholar 

  3. Vourganti, S. et al. Multiparametric magnetic resonance imaging and ultrasound fusion biopsy detect prostate cancer in patients with prior negative transrectal ultrasound biopsies. J. Urol. 188, 2152–2157 (2012).

    Article  Google Scholar 

  4. Rosenkrantz, A. B. et al. Prostate magnetic resonance imaging and magnetic resonance imaging targeted biopsy in patients with a prior negative biopsy: a consensus statement by AUA and SAR. J. Urol. 196, 1613–1618 (2016).

    Article  Google Scholar 

  5. Calio, B. et al. Changes in prostate cancer detection rate of MRI-TRUS fusion versus systematic biopsy over time: evidence of a learning curve. Prostate Cancer Prostatic Dis. 20, 436–441 (2017).

    Article  CAS  Google Scholar 

  6. Ahmed, H. U. et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet 389, 815–822 (2017).

    Article  Google Scholar 

  7. Rouviere, O. et al. Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study. Lancet Oncol. 20, 100–109 (2018).

    Article  Google Scholar 

  8. Hale, G. R. et al. Comparison of elastic and rigid registration during magnetic resonance imaging/ultrasound fusion-guided prostate biopsy: a multi-operator phantom study. J. Urol. 200, 1114–1121 (2018).

    Article  Google Scholar 

  9. Greer, M. D. et al. Computer-aided diagnosis prior to conventional interpretation of prostate mpMRI: an international multi-reader study. Eur. Radiol. 28, 4407–4417 (2018).

    Article  Google Scholar 

  10. Mehralivand, S. et al. A magnetic resonance imaging-based prediction model for prostate biopsy risk stratification. JAMA Oncol. 4, 678–685 (2018).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Peter A. Pinto.

Ethics declarations

Competing interests

The NIH and Philips have a Cooperative Research and Development Agreement. The NIH has intellectual property in the field, including among other patents and patent applications, Patent: “System, methods, and instrumentation for image guided prostate treatment” US Patent number: 8948845, with inventors/author P.A.P. The NIH and Philips (InVivo Inc) have a licensing agreement. The NIH and authors receive royalties for a licensing agreement with Philips/InVivo Inc. The NIH does not endorse or recommend any commercial products, processes or services. The views and personal opinions of the authors expressed herein do not necessarily state or reflect those of the US Government, nor reflect any official recommendation nor opinion of the NIH nor the National Cancer Institute.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lebastchi, A.H., Pinto, P.A. The role of multiparametric MRI in biopsy-naive prostate cancer. Nat Rev Urol 16, 276–277 (2019). https://doi.org/10.1038/s41585-019-0173-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41585-019-0173-7

This article is cited by

Search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research